Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration

Bradley J. Zins, William J. Sandborn, Dennis C. Mays, George M. Lawson, Jeffrey A. McKinney, William J. Tremaine, Douglas W. Mahoney, Alan R. Zinsmeister, Richard D. Hurt, Kenneth P. Offord, James J. Lipsky

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Ulcerative colitis is predominantly a disease of nonsmokers, and transdermal nicotine is therapeutic but often results in adverse reactions. Colonic administration of nicotine tartrate as a liquid enema could decrease systemic nicotine absorption and adverse reactions. The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 μg nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 μg nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (± SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 ± 18%, hydrophilic basic 16 ± 16%, bydrophobic acidic 25 ± 17%, hydrophobic basic 15 ± 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 ± 25%). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. The therapeutic potential of nicotine tartrate liquid enemas, which can potentially limit toxicity by local (colonic) delivery of high doses of nicotine should be investigated in patients with left-sided ulcerative colitis.

Original languageEnglish (US)
Pages (from-to)426-436
Number of pages11
JournalJournal of Clinical Pharmacology
Volume37
Issue number5
StatePublished - May 1997

Fingerprint

Enema
Nicotine
Intravenous Administration
Oral Administration
Pharmacokinetics
Biological Availability
Ulcerative Colitis
Serum

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zins, B. J., Sandborn, W. J., Mays, D. C., Lawson, G. M., McKinney, J. A., Tremaine, W. J., ... Lipsky, J. J. (1997). Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal of Clinical Pharmacology, 37(5), 426-436.

Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. / Zins, Bradley J.; Sandborn, William J.; Mays, Dennis C.; Lawson, George M.; McKinney, Jeffrey A.; Tremaine, William J.; Mahoney, Douglas W.; Zinsmeister, Alan R.; Hurt, Richard D.; Offord, Kenneth P.; Lipsky, James J.

In: Journal of Clinical Pharmacology, Vol. 37, No. 5, 05.1997, p. 426-436.

Research output: Contribution to journalArticle

Zins, BJ, Sandborn, WJ, Mays, DC, Lawson, GM, McKinney, JA, Tremaine, WJ, Mahoney, DW, Zinsmeister, AR, Hurt, RD, Offord, KP & Lipsky, JJ 1997, 'Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration', Journal of Clinical Pharmacology, vol. 37, no. 5, pp. 426-436.
Zins BJ, Sandborn WJ, Mays DC, Lawson GM, McKinney JA, Tremaine WJ et al. Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. Journal of Clinical Pharmacology. 1997 May;37(5):426-436.
Zins, Bradley J. ; Sandborn, William J. ; Mays, Dennis C. ; Lawson, George M. ; McKinney, Jeffrey A. ; Tremaine, William J. ; Mahoney, Douglas W. ; Zinsmeister, Alan R. ; Hurt, Richard D. ; Offord, Kenneth P. ; Lipsky, James J. / Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration. In: Journal of Clinical Pharmacology. 1997 ; Vol. 37, No. 5. pp. 426-436.
@article{5d31082ce7554ff3a0410e4b621e2cee,
title = "Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration",
abstract = "Ulcerative colitis is predominantly a disease of nonsmokers, and transdermal nicotine is therapeutic but often results in adverse reactions. Colonic administration of nicotine tartrate as a liquid enema could decrease systemic nicotine absorption and adverse reactions. The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 μg nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 μg nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (± SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 ± 18{\%}, hydrophilic basic 16 ± 16{\%}, bydrophobic acidic 25 ± 17{\%}, hydrophobic basic 15 ± 12{\%}) were similar to the bioavailability of nicotine after administration by oral solution (20 ± 25{\%}). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100{\%}). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. The therapeutic potential of nicotine tartrate liquid enemas, which can potentially limit toxicity by local (colonic) delivery of high doses of nicotine should be investigated in patients with left-sided ulcerative colitis.",
author = "Zins, {Bradley J.} and Sandborn, {William J.} and Mays, {Dennis C.} and Lawson, {George M.} and McKinney, {Jeffrey A.} and Tremaine, {William J.} and Mahoney, {Douglas W.} and Zinsmeister, {Alan R.} and Hurt, {Richard D.} and Offord, {Kenneth P.} and Lipsky, {James J.}",
year = "1997",
month = "5",
language = "English (US)",
volume = "37",
pages = "426--436",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - Pharmacokinetics of nicotine tartrate after single-dose liquid enema, oral, and intravenous administration

AU - Zins, Bradley J.

AU - Sandborn, William J.

AU - Mays, Dennis C.

AU - Lawson, George M.

AU - McKinney, Jeffrey A.

AU - Tremaine, William J.

AU - Mahoney, Douglas W.

AU - Zinsmeister, Alan R.

AU - Hurt, Richard D.

AU - Offord, Kenneth P.

AU - Lipsky, James J.

PY - 1997/5

Y1 - 1997/5

N2 - Ulcerative colitis is predominantly a disease of nonsmokers, and transdermal nicotine is therapeutic but often results in adverse reactions. Colonic administration of nicotine tartrate as a liquid enema could decrease systemic nicotine absorption and adverse reactions. The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 μg nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 μg nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (± SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 ± 18%, hydrophilic basic 16 ± 16%, bydrophobic acidic 25 ± 17%, hydrophobic basic 15 ± 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 ± 25%). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. The therapeutic potential of nicotine tartrate liquid enemas, which can potentially limit toxicity by local (colonic) delivery of high doses of nicotine should be investigated in patients with left-sided ulcerative colitis.

AB - Ulcerative colitis is predominantly a disease of nonsmokers, and transdermal nicotine is therapeutic but often results in adverse reactions. Colonic administration of nicotine tartrate as a liquid enema could decrease systemic nicotine absorption and adverse reactions. The purpose of the current study was to determine the bioavailability and pharmacokinetic parameters of nicotine after administration by hydrophilic liquid enema (acidic and basic), hydrophobic liquid enema (acidic and basic), and by oral and intravenous routes. Thirty healthy volunteers received 45 μg nicotine base/kg (as nicotine tartrate) in one of five formulations (each n = 6): hydrophilic acidic liquid enema, hydrophilic basic liquid enema, hydrophobic acidic liquid enema, hydrophobic basic liquid enema, and oral solution. All participants also received 15 μg nicotine base/kg (as nicotine tartrate) intravenously during a separate study period. Serum concentrations of nicotine were determined by gas chromatography with mass spectrometry. The mean (± SD) bioavailabilities of nicotine after administration in the liquid enema formulations (hydrophilic acidic 17 ± 18%, hydrophilic basic 16 ± 16%, bydrophobic acidic 25 ± 17%, hydrophobic basic 15 ± 12%) were similar to the bioavailability of nicotine after administration by oral solution (20 ± 25%). The bioavailabilities of nicotine for all five nonintravenous formulations were significantly less than for intravenous nicotine (100%). Serum concentrations of nicotine did not predict adverse reactions. Nicotine tartrate administered as either a liquid enema or as an oral solution had low bioavailability and was well tolerated. The therapeutic potential of nicotine tartrate liquid enemas, which can potentially limit toxicity by local (colonic) delivery of high doses of nicotine should be investigated in patients with left-sided ulcerative colitis.

UR - http://www.scopus.com/inward/record.url?scp=8244247101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8244247101&partnerID=8YFLogxK

M3 - Article

C2 - 9156375

AN - SCOPUS:8244247101

VL - 37

SP - 426

EP - 436

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 5

ER -